Pfizer (PFE) surpassed Wall Street analysts’ consensus estimate for EPS (earnings per share) in 4Q17, reporting EPS of $0.62 compared to the estimate of $0.56.
However, Pfizer missed analysts’ consensus revenue estimate, reporting revenue of ~$13.70 billion compared to the estimate of ~$13.72 billion in the quarter.
The above chart shows analysts’ recommendations on Pfizer stock over the last 12 months. For 1Q18, Wall Street analysts expect the company’s revenue to rise ~2.1% to $13.1 billion compared to ~$12.8 billion in 1Q17. Analysts expect Pfizer to report EPS of $0.73 in 1Q18 compared to $0.69 in 1Q17.
Pfizer’s stock price has risen nearly 6.2% over the last 12 months, and it’s risen ~0.4% year-to-date in 2018. Analysts’ estimates show that the stock has the potential to return ~10.5% over the next 12 months. Their recommendations show a 12-month target price of $40.15 per share for the stock compared to its last price of $36.35 on March 14, 2018.
As of March 15, 2018, there are 23 analysts tracking Pfizer. Of these 23 analysts, 12 have recommended “buys” on the stock, nine have recommended “holds” on the stock, and two have recommended “sells.” The consensus rating for Pfizer stands at 2.57, which represents a moderate “buy” for value investors. Changes in analysts’ estimates and recommendations are based on company performance and changing trends in a stock’s price.